Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.

Investors with a lot of money to spend have taken a bullish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.

Better-than-expected Alzheimer's disease treatment sales and a quarterly beat not enough to offset below-consensus EPS outlook Biogen Inc.'s stock (BIIB) fell 0.6% early Wednesday, after the ...